#### Classification and prediction of frontotemporal dementia based on plasma microRNAs

Iddo Magen<sup>1</sup>, Nancy Sara Yacovzada<sup>1</sup>, Jason D. Warren<sup>2</sup>, Carolin Heller<sup>2,3</sup>, Imogen Swift<sup>2,3</sup>, Yoana Bobeva<sup>4</sup>, Andrea Malaspina<sup>4</sup>, Jonathan D. Rohrer<sup>2\*</sup> Pietro Fratta<sup>5\*</sup> and Eran Hornstein<sup>1\*</sup>

1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2 Dementia Research Centre, and 3 UK Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

4 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

5 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

\* To whom correspondence should be addressed: <u>j.rohrer@ucl.ac.uk; p.fratta@ucl.ac.uk;</u> eran.hornstein@weizmann.ac.il;

Abstract word count: 242.

Text word count (excluding references and figure legends): 3528.

No. of items (figures, tables): 4, 2

References: 38

### 2 Abstract

3 Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder characterized by frontal and temporal lobe atrophy, typically manifesting with behavioural or language 4 impairment. Because of its heterogeneity and lack of available diagnostic laboratory tests there 5 can be a substantial delay in diagnosis. Cell-free, circulating, microRNAs are increasingly 6 7 investigated as biomarkers for neurodegeneration, but their value in FTD is not yet established. In this study, we investigate microRNAs as biomarkers for FTD diagnosis. We performed next 8 generation small RNA sequencing on cell-free plasma from 52 FTD cases and 21 controls. The 9 analysis revealed the diagnostic importance of 20 circulating endogenous miRNAs in 10 11 distinguishing FTD cases from controls. The study was repeated in an independent second cohort of 117 FTD cases and 35 controls. The combinatorial microRNA signature from the first cohort, 12 precisely diagnosed FTD samples in a second cohort. To further increase the generalizability of 13 14 the prediction, we implemented machine learning techniques in a merged dataset of the two cohorts, which resulted in a comparable or improved classification precision with a smaller panel 15 of miRNA classifiers. In addition, there are intriguing molecular commonalities with cell free 16 miRNA signature in ALS, a motor neuron disease that resides on a pathological continuum with 17 FTD. However, the signature that describes the ALS-FTD spectrum is not shared with blood 18 19 miRNA profiles of patients with multiple sclerosis. Thus, microRNAs are promising FTD biomarkers that might enable earlier detection of FTD and improve accurate 20 identification of patients for clinical trials 21

## 23 Introduction

Frontotemporal dementia (FTD) is a clinically and neuroanatomically heterogeneous neurodegenerative disorder characterized by frontal and temporal lobe atrophy. It typically manifests between the ages of 50 and 70 with behavioral or language problems, and below the age of 65 is the second most common form of dementia, after Alzheimer's disease (1).

28

Due to heterogeneity in clinical presentation FTD can be difficult to diagnose (2). Three main phenotypes are described: behavioral variant frontotemporal dementia (bvFTD), characterized by changes in social behaviour and conduct, semantic dementia (SD), characterized by the loss of semantic knowledge, leading to impaired word comprehension, and progressive non-fluent aphasia (PNFA), characterized by progressive difficulties in speech production (2, 3).

34

FTD is also pathologically heterogeneous with inclusions seen containing hyperphosphorylated tau (4), TDP- 43 (5), or fused in sarcoma (FUS) (6, 7). Mutations in the genes encoding for these proteins, as well as in other genes such as progranulin (GRN), chromosome 9 open reading frame 72 (C9ORF72), valosin-containing protein (VCP), TANK-binding kinase 1 (TBK1) and charged multivesicular body protein 2B (CHMP2B) are also associated with FTD (8-11).

40

FTD overlaps clinically, pathologically and genetically with several other degenerative disorders.
In particular, there is often overlap with amyotrophic lateral sclerosis (ALS): one in 5 ALS
patients meets the clinical criteria for a concomitant diagnosis of FTD, and one in eight FTD
patients is also diagnosed with ALS. TDP-43 inclusions are observed in the brains of both people

with FTD and ALS, and genetic evidence supports that these diseases reside along a continuum(5, 12-14).

47

Previous studies have aimed to develop cell-free biomarkers for FTD, including TDP-43 (15), 48 tau (16), and neurofilament light chain (NfL) (17), but none of these have shown use for 49 50 diagnosis. microRNAs (miRNAs), endogenous non-coding RNAs, can be quantified in biofluids 51 (18), and have been shown previously to be dysregulated in amyotrophic lateral sclerosis (ALS) and in FTD (19). Furthermore, they may be biomarkers of disease progression in other brain 52 53 diseases, including ALS (20). Previous studies have assessed the initial potential of microRNAs as diagnostic FTD biomarkers including miRNA analysis in plasma (21, 22), CSF and serum 54 (23), and CSF exosomes (24) but no definitive markers have so far been found. We therefore 55 aimed to study a large cohort of patients with different clinical phenotypes and pathological 56 forms of FTD, to see whether they are able to reliably distinguish cases from controls, and 57 different forms of FTD from each other. 58

59

Here, we provide an unbiased signature of plasma miRNAs that has good diagnostic power in a large and heterogeneous cohort of patients with FTD, which is further predictive in an independent second cohort and may contribute to FTD subtyping. Therefore, circulating miRNAs hold a fascinating potential as diagnostic biomarkers and as means for patient stratification in clinical trials.

65

66

## 68 **Results**

### 69 A plasma miRNA classifier for FTD

In order to characterize the potential of plasma miRNAs as biomarkers for FTD we assembled a 70 cohort of 73 plasma samples (subject information in Table 1), purified RNA and performed next 71 generation sequencing (NGS). As many as 2313 individual miRNA species were aligned to the 72 human genome (GRCh37/hg19) across all samples. However, only 137 miRNA species 73 exceeded a cut-off of  $\geq 100$  UMIs per sample averaged on all samples. Of the 137 detected 74 miRNAs, 20 miRNA changed in a statistically significant manner in FTD plasma relative to 75 76 control (p-value < 0.05, Wald test; Figure 1A). Two miRNAs, whose levels decreased to the greatest extent in FTD compared to controls, namely, miR-379-5p and miR-654-3p (1.4 fold), 77 78 remained significant after multiple hypothesis testing (Figure 1B).

79

We next studied miRNA capacity as binary disease classifiers, by generating receiver-operating
characteristic (ROC) curves. ROC area under the curve (AUC) suggested modest predictive
capacity for miR-379-5p and for miR-654-3p (AUC for both: 0.71±0.07, p<0.01; Figure 1C).</li>

83

We further utilized the combinatorial signature of the 20 miRNAs that were differentially expressed between FTD patient plasma and control (Table S1). Using these, an ROC AUC of  $0.79\pm0.05$  (p<0.0001, Fig. 1C) was found, which was superior to the prediction capacity of any individual miRNA.

88

## 90 Assessment of plasma miRNA classifier for FTD in a second cohort

We then performed a replication study in an independent cohort of 117 FTD cases and 35 agematched controls (Table 1). In this study, the levels of 58 miRNAs decreased and 89 increased in a statistically significant manner in FTD, relative to control plasma (p-value <0.05, Wald test, Figure 2A and Table S1). Noticeable miRNAs were miR-125b-2-3p (× 26 up, p =  $1.4 \times 10^{-25}$ ), miR-34b-5p (× 23 up, adj. p =  $9.8 \times 10^{-23}$ ) and miR-379-5p (× 2.2 down, p =  $1.9 \times 10^{-14}$ ). 144 of the 147 miRNAs further survived adjustment for multiple comparisons by Benjamini–Hochberg procedure (adjusted p-value < 0.05).

98

The expression of the 20 miRNAs that were most differentially expressed in the first cohort correlated with their respective expression in the second cohort (Pearson R of log 2 fold-change = 0.75, p=0.0001, Fig. 2B). Furthermore, the combined predictive power of the 20 miRNAs, that were decided on as a classifier based on data of the first cohort, was slightly superior in the replication cohort, with an AUC of  $0.82\pm0.04$  (p<0.0001, Fig. 2C).

104

In addition to external validation, by testing a second cohort, we sought to guarantee the 105 generalizability by applying K-fold cross-validation, which is an internal validation technique to 106 evaluate performance and prevent overfitting (25, 26). Towards this we divided the 225 datasets 107 108 (from 56 control and 169 FTD samples) randomly into three equal parts, or 'folds', of 75 datasets, each. A machine learning model was trained using each time 2 of the 3 data folds (150 109 samples) for building a prediction model and applying the prediction rule to estimate the 110 111 prediction precision on the remaining 75 samples in the remaining third fold. This step was repeated k = 3 times iteratively so all folds were used twice in training and once for the testing 112

process. 136 miRNAs that were measured above noise levels in all cohorts were included,
yielding the following AUCs: 0.90 for fold 1; 0.87 for fold 2; and 0.93 for fold 3, with an
average AUC of 0.90 (Fig. 2D).

116

We next aimed to reduce the complexity of the measurements required for prediction by 117 identifying the top 20 miRNA predictors per fold, i.e. the 20 miRNAs with the highest weighted 118 importance in predicting disease status (Fig. 3A-C). We reduced the number of miRNAs 119 gradually, starting from a 43 miRNA panel composed of the top 20 predictors in at least one fold 120 (i.e., in one, two or three folds), which resulted in AUCs of 0.87, 0.87, 0.94 and an average AUC 121 of 0.89 (Fig. 3D). We then utilized 13 miRNAs that were among the top 20 in at least two folds 122 123 which resulted in AUCs of 0.85, 0.89 and 0.93, and an average of 0.89 (Fig. 3E). Finally, we used only four miRNAs - miR-26a-5p, miR-326, miR-203a-3p and miR-629-5p - that were 124 among the top 20 predictors in all three folds. Their combinatorial AUCs after cross-validation 125 126 were 0.81, 0.83 and 0.89 and 0.85 on average (Fig. 3F). All panels of miRNAs used for the 127 cross-validation are listed in Table S1.

128

These measurements were comparable to the AUC obtained with 136 miRNAs (Fig. 2D), revealing that the diagnostic power was not compromised by a substantial reduction of the miRNA numbers.

132

133

134

## 136 Overlap between FTD miRNA signature and ALS miRNA signature

FTD and ALS are two diseases on a neuropathology continuum. We aimed to determine whether 137 the miRNA signatures found in FTD and in ALS reveal any molecular similarity. For this 138 139 purpose, we sequenced and analyzed the differences between 115 ALS cases and 103 controls (see Table 2). We also sequenced 17 samples from patients with multiple sclerosis (MS), because 140 141 this disease is mechanistically different from FTD and involves autoimmune-related demyelination, so molecular similarity to FTD is not expected to be seen. 161 miRNA species 142 were differentially expressed in either one of the diseases (FTD, ALS or MS) vs controls. 143 144 Differentially expressed miRNAs in either FTD or ALS were correlated in fold-change values between the diseases (Pearson R for log-transformed values = 0.35, p<0.0001, Figure 4A), but no 145 146 such correlation was found between FTD and MS (R= - 0.15, p=0.15, Figure 4B). Intriguingly, muscle-specific miR-206 robustly increases in ALS, in agreement with previous reports (27-30) 147 with no change at all in FTD. 148

149

150 We next tested the degree of overlap between miRNAs differentially expressed in FTD vs. ALS. 151 Seven out of 20 miRNAs changed exclusively in FTD, and the remaining 13 miRNAs changed 152 in a significant manner in both FTD and ALS (Figure 4C; Table S1). Remarkably, the 153 directionality of change for these miRNAs (increase/decrease) was consistent across diseases for 154 all of the miRNAs but one, miR-29a-3p which decreased in FTD and increased in ALS (Figure 155 4A). Moreover, the fold-change values in this subset of 13 miRNAs that have changed in both ALS and FTD, were highly correlated between the diseases (Pearson R = 0.90, p<0.0001). In 156 contrast, only five out of the 20 miRNAs that changed in FTD, also changed in MS (Figure 4D; 157 158 Table S1). Taken together, the miRNA signature in FTD plasma shows a similarity to the ALS

plasma signature, but not to the MS signature, in accordance with pathological and clinicalsimilarities between FTD and ALS.

161

Finally, we employed the FTD predictor, based on 20 miRNAs that are changing in FTD on ALS and healthy control cohorts. The signature of 20 miRNAs was able to correctly call ALS from controls more than at random (ROC AUC = 0.63, p<0.001, Table S2), while the seven miRNAs that are exclusively changed in FTD were not able to distinguish between ALS and control in a statistically significant manner (ROC AUC = 0.57, p=0.06). Thus, miRNAs that are differentially expressed in FTD have a moderate capacity to predict ALS.

168

# 169 miRNAs signature of FTD subtypes and FTD patients with different pathologies

We next tested whether specific miRNAs changed in the main FTD subtypes, bvFTD, SD and PNFA. After statistical adjustment for multiple comparisons, four miRNAs decreased in a significant manner in PNFA, and two miRNAs decreased and one miRNA increased significantly in bvFTD, whereas the small SD sample numbers (n=8) did not allow to depict microRNAs that are changed in a significant manner after adjustment for multiple comparisons (Fig. S1A-C).

176

We calculated a decent combinatorial predictive power for the 20 miRNAs in distinguishing bvFTD / SD / PNFA from healthy controls: thus, for bvFTD vs. healthy controls in the original cohort we obtained an AUC of  $0.85\pm0.06$ , p<0.0001; in the replication cohort AUC of  $0.80\pm0.05$ , p<0.0001, Fig. S1D; for SD vs. controls, original cohort AUC was  $0.86\pm0.08$ ,

p=0.003; replication cohort AUC was 0.79±0.06, p=0.0003 (Fig. S1E); for PNFA vs. controls,
original cohort AUC was 0.81±0.08, p=0.002; replication cohort AUC was 0.81±0.05, p<0.0001</li>
(Fig. S1F). We concluded that the combinatorial 20 miRNAs signature distinguishes FTD and its
subtypes from controls with comparable AUCs, for all three subtypes.

185

186 The overlap of symptoms between subtypes of FTD poses a diagnostic challenge (31). We 187 therefore tested whether FTD subtypes could be distinguished based on miRNA signature. We analyzed miRNA differential expression of PNFA cases vs. non-PNFA, which pooled together 188 189 bvFTD and SD cases, due to a similar molecular signature of SD and bvFTD. Fourteen miRNAs changed in a significant manner in PNFA vs non-PNFA: miR-625-3p, miR-625-5p, miR-126-5p, 190 191 miR-146a-5p, miR-146b-5p, miR-340-5p, miR-181a-5p (all increased in PNFA compared to 192 non-PNFA) and miR-342-3p, let-7d-3p, miR-122-5p, miR-192-5p, miR-16-5p, miR-203a-3p 193 (decreased; Fig. S1G). The combinatorial signature of these fourteen miRNAs yielded an AUC 194 of 0.81±0.08 (Fig. S1H; p=0.0007), indicating that PNFA can be differentiated from other types 195 of FTD with a high accuracy.

196

We also tested whether specific miRNAs changed between FTD cases with different likely underlying pathologies, i.e. tau and TDP-43. 19 FTD cases with predicted Tau pathology based on genetics (4 in cohort I + 15 in cohort II) were compared to 63 cases with predicted TDP-43 pathology (23 in cohort I + 40 in cohort II). Fourteen miRNAs changed in a statistically significant manner, but none remained significant after correction for multiple hypotheses (Fig. S2A). The combinatorial signature of these 14 miRNAs had a weak classification power, though it was statistically significant (AUC of ROC =  $0.7\pm0.06$ , p=0.009, Fig. S2B). Taken together, the

- 204 miRNA profile in our dataset has limited diagnostic power for pathological subtypes of FTD, as
- 205 opposed to FTD vs control and different clinical subtypes of FTD.

206

## 208 Discussion

209 Our study utilizes a large cohort of FTD blood samples. It is the first work that employs next generation sequencing technology for FTD biomarkers. We defined a signature, composed of 20 210 miRNAs, that is able to classify FTD. This signature that was discovered in an initial cohort was 211 informative when applied to a second cohort. These observations suggest that miRNAs can be 212 potentially utilized in clinical sampling as diagnostic FTD markers, which is needed because of 213 non-specific early symptoms and overlap with other degenerative and non-degenerative 214 conditions. Ours is the largest cohort used for miRNA profile, and its use of unbiased exhaustive 215 next generation sequencing can potentially explain the discrepancies from past studies with 216 217 smaller cohorts and biased miRNA choices (21-24).

218 A classifier panel of 20 miRNAs had ~80% chance to correctly call FTD in the first cohort. Reassuringly, it was comparably informative in calling FTD correctly also on a second cohort. In 219 addition to external (second cohort) validation, we applied machine learning to the whole dataset 220 221 of 225 samples. Through iterative learning, we defined a signature created by 136 miRNAs that 222 was able to call FTD correctly in 90% of cases. We then reduced the signature complexity to the 223 usage of only 43 miRNAs with the highest classification power that kept a true FTD calling 224 capacity of 90%. Toward clinical diagnostic usage it is warranted to test the predictor that was developed in machine learning on an independent cohort, preferentially of different ethnicity. 225

226

Interestingly, the miRNA signatures of FTD is akin of ALS perhaps reflecting on a shared pathomechanism for these two neurodegenerative disorders on the ALS-FTD continuum. This similarity cannot be extended to multiple sclerosis, a disease that is driven by a different,

230	autoimmune, mechanism. Nonetheless, the two diseases are still two different entities and
231	accordingly only 10% of the miRNAs that has changed in either disease were shared.
232	

233	In summary, we have characterized a large FTD plasma cohort for miRNA expression by next
234	generation sequencing and found specific patterns of changes that can contribute to diagnosis of
235	FTD. These patterns seem to involve the ALS-FTD continuum, alluding to differences and
236	commonalities in the underlying mechanisms that drive molecular changes in ALS and FTD.
237	

### 239 Materials and Methods

### 240 Standard protocol approvals, registrations, and patient consents

Approvals were obtained from the local research ethics committee and all participants provided written consent (or gave verbal permission for a carer to sign on their behalf). For ALS samples, recruitment, sampling procedures and data collection have been performed according to Protocol (Protocol number 001, version 5.0 Final – 30th November 2015).

#### 245 Study design

Based on power analysis, we found that about 20 control and 50 FTD samples are required to obtain an ROC of 0.7 with a power of 80% and a p-value of 0.05. We determined the sample size based on these calculations. Because sample processing was done in different batches, samples were randomly allocated to the batches and within each batch, the number of control and FTD/ALS/MS samples was balanced in order to reduce batch-associated bias.

### 251 Participants and sampling

252 Participants were enrolled in the longitudinal FTD cohort studies at UCL. Frozen plasma samples from the UCL FTD Biobank were shipped to the Weizmann Institute of Science for 253 molecular analysis. Study cohort I: 52 FTD patients, 21 healthy controls. Study cohort II: 117 254 255 FTD patients, 35 healthy controls. FTD patients were further assigned into two groups with predicted pathology of TDP-43 or tau, based on genetics and clinical phenotype. Patients 256 positive for C9ORF72 repeats and progranulin (PRGN) mutations and/or presented with 257 semantic dementia, were predicted to have TDP-43 pathology, while patients with MAPT 258 mutations were predicted to have tau pathology. Demographic data are detailed in table 1. 259

ALS and MS samples and their respective healthy controls (N = 115, 17 and 103, respectively) were obtained from the ALS biomarker study. ALS patients were diagnosed according to

standard criteria by experienced ALS neurologists (32). Healthy controls were typically spousesor relatives of patients. Demographic data are detailed in table 2.

Plasma samples were stored in -80°C until RNA extraction and subsequent small RNA next
 generation sequencing.

266

#### 267 Small RNA next generation sequencing

Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany) 268 and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher 269 Scientific, Waltham, MA). For small RNA next generation sequencing (NGS), libraries were 270 271 prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit and QIAseq miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. 272 Following 3' and 5' adapter ligation, small RNA was reverse transcribed, using unique 273 274 molecular identifier (UMI), primers of random 12-nucleotide sequences. This way, precise linear quantification miRNA is achieved, overcoming potential PCR-induced biases (18). cDNA 275 libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide 276 unique index. Following size selection and cleaning of libraries with magnetic beads, quality 277 278 control was performed by measuring library concentration with Qubit fluorometer using dsDNA 279 high sensitivity (HS) assay kit (Thermo Fisher Scientific, Waltham, MA) and confirming library 280 size with Tapestation D1000 (Agilent). Libraries with different indices were multiplexed and 281 sequenced on a single NextSeq 500/550 v2 flow cell (Illumina), with 75bp single read and 6bp 282 index read. Fastq files were demultiplexed using the User-friendly Transcriptome Analysis 283 Pipeline (UTAP) developed at the Weizmann Institute (33). Sequences were mapped to the human genome using Qiagen GeneGlobe analysis web tool. 284

285

# 286 Statistical analysis and machine learning

Plasma samples with  $\geq$ 40,000 total miRNA UMIs were included. miRNA with average 287 abundance of  $\geq 100$  UMIs per sample, across all samples, were considered above noise levels. 288 miRNA NGS data was analyzed via DESeq2 package in R Project for Statistical Computing (34, 289 290 35), under the assumption that miRNA counts followed negative binomial distribution and data were corrected for library preparation batch in order to reduce its potential bias. Ratio of 291 normalized FTD counts to the normalized control counts presented after logarithmic 292 293 transformation on base 2. P values were calculated by Wald test (35, 36) and adjusted for multiple testing according to Benjamini and Hochberg (37). For binary classification by 294 miRNAs, receiver operating characteristic (ROC) curves for individual miRNAs or combinations 295 296 of miRNAs were plotted based on voom transformation of gene expression data in R (38). Graphs were generated with GraphPad Prism 5. 297

Machine learning was performed on Python 3.6. Cohorts were merged and case-control number 298 imbalance mitigated applying ADASYN algorithm (https://imbalanced-299 was by 300 learn.readthedocs.io/en/stable/api.html), which simulates synthetic new healthy sample data from 301 the existing data. Then, K-Fold cross validation was performed on the pooled data set with K=3. An ROC was generated for each of the three folds and individual and mean AUCs were 302 calculated. 303

304

### 306 Acknowledgements

We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD, ALS, MS and healthy volunteers for their contribution and ALS biomarkers study coworkers for biobanking, which has made this study possible (REC 09/H0703/27). We also thank the the North Thames Local Research Network (LCRN) for its support. EH is the Mondry Family Professorial Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases.

313

#### 314 Funding

EH was supported by the ISF Legacy 828/17 grant, Target ALS 118945 grant, European 315 Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) 316 / ERC grant agreement n° 617351. Israel Science Foundation, the ALS-Therapy Alliance, AFM 317 Telethon 20576 grant, Motor Neuron Disease Association (UK), The Thierry Latran Foundation 318 for ALS research, ERA-Net for Research Programmes on Rare Diseases (FP7), A. Alfred 319 Taubman through IsrALS, Yeda-Sela, Yeda-CEO, Israel Ministry of Trade and Industry, Y. 320 Leon Benoziyo Institute for Molecular Medicine, Benoziyo Center Neurological Disease, Kekst 321 322 Family Institute for Medical Genetics, David and Fela Shapell Family Center for Genetic Disorders Research, Crown Human Genome Center, Nathan, Shirley, Philip and Charlene Vener 323 324 New Scientist Fund, Julius and Ray Charlestein Foundation, Fraida Foundation, Wolfson Family 325 Charitable Trust, Adelis Foundation, MERCK (UK), Maria Halphen, Estates of Fannie Sherr, Lola Asseof, Lilly Fulop, E. and J. Moravitz. Teva Pharmaceutical Industries Ltd. as part of the 326 327 Israeli National Network of Excellence in Neuroscience (NNE) postdoc Fellowship to IM 328 117941. The Dementia Research Centre is supported by Alzheimer's Research UK, Brain

- 329 Research Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen
- 330 Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and
- the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as
- 332 well as an Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician
- 333 Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease
- 334 Translational Research Collaboration (BRC149/NS/MH). PF is supported by an MRC/MND
- LEW Fellowship and by the NIHR UCLH BRC. This work was also supported by the Motor
- 336 Neuron Disease Association (MNDA) 839-791
- 337

# 338 Competing interests

- 339 The authors state that they have no competing interests.
- 340

# 341 **References**

Harvey RJ, Skelton-Robinson M, and Rossor MN. The prevalence and causes of
 dementia in people under the age of 65 years. *J Neurol Neurosurg Psychiatry*. 2003;74(9):1206 9.

Rabinovici GD, and Miller BL. Frontotemporal lobar degeneration: epidemiology,
 pathophysiology, diagnosis and management. *CNS Drugs*. 2010;24(5):375-98.

347 3. Snowden JS, Neary D, and Mann DM. Frontotemporal dementia. *Br J Psychiatry*.
348 2002;180:140-3.

4. Lee G, and Leugers CJ. Tau and tauopathies. *Prog Mol Biol Transl Sci.* 2012;107:263-93.

- 5. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al.
  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 2006;314(5796):130-3.
- Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, and Mackenzie IR. A
  new subtype of frontotemporal lobar degeneration with FUS pathology. *Brain*. 2009;132(Pt
  11):2922-31.
- Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, and Mackenzie IR.
  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. *Acta Neuropathol.* 2009;118(5):605-16.
- 8. Fontana F, Siva K, and Denti MA. A network of RNA and protein interactions in Fronto
  Temporal Dementia. *Front Mol Neurosci.* 2015;8:9.
- 361 9. Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, et al. The
  362 genetics and neuropathology of frontotemporal lobar degeneration. *Acta Neuropathol.*363 2012;124(3):353-72.
- 10. van Swieten J, and Spillantini MG. Hereditary frontotemporal dementia caused by Tau
  gene mutations. *Brain Pathol.* 2007;17(1):63-73.
- Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R, et al. Wholegenome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal
  lobar degeneration without motor neuron disease. *Acta Neuropathol.* 2015;130(1):77-92.
- Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of
  the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and
  frontotemporal dementia: a cross-sectional study. *Lancet Neurol.* 2012;11(4):323-30.
- Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A
  hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALSFTD. *Neuron.* 2011;72(2):257-68.
- van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al.
  Amyotrophic lateral sclerosis. *Lancet*. 2017;390(10107):2084-98.
- Feneberg E, Gray E, Ansorge O, Talbot K, and Turner MR. Towards a TDP-43-Based
  Biomarker for ALS and FTLD. *Mol Neurobiol*. 2018;55(10):7789-801.
- Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong
  FJ, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal
  dementia spectrum. *Neurology*. 2018;90(14):e1231-e9.
- 382 17. Skillback T, Mattsson N, Blennow K, and Zetterberg H. Cerebrospinal fluid
   383 neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts
   384 survival. *Amyotroph Lateral Scler Frontotemporal Degener*. 2017;18(5-6):397-403.

- 18. Coenen-Stass AML, Magen I, Brooks T, Ben-Dov IZ, Greensmith L, Hornstein E, et al.
- Evaluation of methodologies for microRNA biomarker detection by next generation sequencing.
   *RNA Biol.* 2018;15(8):1133-45.
- Eitan C, and Hornstein E. Vulnerability of microRNA biogenesis in FTD-ALS. *Brain Res.* 2016.
- 390 20. Magen I, Coenen-Stass A, Malaspina A, Greensmith L, Lu CH, Fratta P, et al.
- Circulating miRNAs as prognostic and longitudinal markers for amyotrophic lateral sclerosis. In
   preparation.
- Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, et al.
  Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of
  neurodegenerative diseases. *Alzheimers Res Ther.* 2017;9(1):89.
- 396 22. Grasso M, Piscopo P, Talarico G, Ricci L, Crestini A, Tosto G, et al. Plasma microRNA
   397 profiling distinguishes patients with frontotemporal dementia from healthy subjects. *Neurobiol* 398 *Aging*. 2019.
- 23. Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML, et al.
  Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of
  frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. *PLoS One.* 2018;13(5):e0197329.
- 24. Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, et al.
  Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. *J Neurol Neurosurg Psychiatry*. 2018;89(8):851-8.
- Al-Hameed S, Benaissa M, Christensen H, Mirheidari B, Blackburn D, and Reuber M. A
  new diagnostic approach for the identification of patients with neurodegenerative cognitive
  complaints. *PLoS One.* 2019;14(5):e0217388.
- 409 26. Baek S, Tsai CA, and Chen JJ. Development of biomarker classifiers from high-410 dimensional data. *Brief Bioinform*. 2009;10(5):537-46.
- 411 27. de Andrade HM, de Albuquerque M, Avansini SH, de SRC, Dogini DB, Nucci A, et al.
  412 MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral
  413 sclerosis. *J Neurol Sci.* 2016;368:19-24.
- 414 28. Tasca E, Pegoraro V, Merico A, and Angelini C. Circulating microRNAs as biomarkers
  415 of muscle differentiation and atrophy in ALS. *Clin Neuropathol.* 2016;35(1):22-30.
- 416 29. Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, and Osta R.
- 417 MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis.
   418 *PLoS One.* 2014;9(2):e89065.
- 30. Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, et al. Serum
  miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis
  (ALS). *Neurobiol Aging*. 2017;55:123-31.
- 422 31. Hodges JR, and Piguet O. Progress and Challenges in Frontotemporal Dementia
  423 Research: A 20-Year Review. *J Alzheimers Dis.* 2018;62(3):1467-80.
- 424 32. Brooks BR, Miller RG, Swash M, Munsat TL, and World Federation of Neurology
- Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of
  amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord*.
  2000;1(5):293-9.
- 428 33. Kohen R, Barlev J, Hornung G, Stelzer G, Feldmesser E, Kogan K, et al. UTAP: User-
- 429 friendly Transcriptome Analysis Pipeline. *BMC bioinformatics*. 2019;24:154.

- 430 34. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, 431 Austria. R Foundation for Statistical Computing 2015.
- Love MI, Huber W, and Anders S. Moderated estimation of fold change and dispersion 432 35. 433 for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
- 434 Anders S, and Huber W. Differential expression analysis for sequence count data. 36. Genome Biol. 2010;11(10):R106. 435
- 436 Benjamini Y, Drai D, Elmer G, Kafkafi N, and Golani I. Controlling the false discovery 37.
- 437 rate in behavior genetics research. Behav Brain Res. 2001;125(1-2):279-84.
- Law CW, Chen Y, Shi W, and Smyth GK. voom: Precision weights unlock linear model 38. 438
- 439 analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.

440

Magen et al Table 1

	Cohort I		Cohort II	
	Control	FTD	Control	FTD
Number of subjects (% males)	21 (62%)	52 (60%)	35 (51%)	117 (68%)
Age at enrolment	52±4 yr.	65±1 yr.	65±1 yr.	66±1 yr.
Age of onset (1 <sup>st</sup> reported symptoms)	N/A	61±1 yr.	N/A	60±1 yr.
Disease duration at enrolment	N/A	4.5±0.3 yr	N/A	6±0.3 yr
Clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others)	N/A	25/15/8/2/2	N/A	57/25/20/3/12
Mutation carriers (C9ORF72/MAPT/ GRN/TBK1)	N/A	6/4/8/1	N/A	12/10/5/1
Likely pathology (TDP-43/Tau)	N/A	23/4	N/A	40/15

Table 1. Summary of demographic and clinical characteristics of FTD Cohorts I and II and
control samples. bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic
dementia

Magen et al Table 2

		Controls	ALS	MS
	Number of subjects (% males)	103 (27.2%)	115 (64.3%)	17 (29.4%)
	Age at enrolment	52±2 yr.	64±1 yr.	57±2 yr.
-	<b>Table 2.</b> Summary of demographic and clin ALSFRS-R: ALS functional rating scale. D of first phlebotomy was significantly differ test: p<0.0001; t-test: p<0.001, respectively)	ical characteristic emographic data ent between ALS	s of ALS, MS an recognizes that 1 5 cohort I and co	d control sample nale ratio and a ontrols (proporti



489

490 Figure 1. Predictive value of differential miRNA expression in FTD plasma. (A) MA plot of differential miRNA expression in FTD (n=52) and heathy control (n=21 plasma samples). Log-2 491 transformed fold-change, against the mean miRNA abundance. Red -significantly changed 492 miRNAs (p-value ≤0.05). (B) A volcano plot of differentially expressed miRNAs between FTD 493 494 (n=52) and heathy control (n=21 plasma samples). Each dot represents a single miRNA, plotted according to log 2 fold-change (FC) in FTD vs control (X-axis), and the negative log 10 495 transformation of p-value (Y-axis). Black horizontal line demarcates p<0.05 and dots denote 496 miRNAs with statistically significant differential expression in FTD plasma; green - increased in 497 498 FTD; blue - decreased in FTD. (C) Receiver operating characteristic (ROC) curves demonstrate 499 the capacity of miR-379-5p (blue, AUC=0.71, p=0.005), miR-654-3p (green, AUC=0.71, p=0.006) and of a combinatorial signature of 20 miRNAs, whose differential expression is 500 501 significant (red, AUC=0.79, p<0.0001; miRNAs listed in Table S1), to distinguish between FTD and healthy controls. True positive rate (sensitivity) as a function of the false positive rate (1-502 503 specificity) for different cut-off values. P-values are calculated given null hypothesis of area 504 under the curve (AUC) = 0.5.

505

506

507

508

509

510

511



515 Figure 2. Replication of miRNA signature in a second cohort. (A) MA plot of differential 516 miRNA expression in a second cohort of FTD (n=117) and a second heathy control cohort (n=35 517 plasma samples). Log-2 transformed fold-change, against the mean miRNA abundance. Red significantly changed miRNAs (p-value  $\leq 0.05$ ). (B). Scatter plot of correlation between fold 518 change of 20 miRNAs, which classify FTD, between the first and second cohorts. (C) ROC 519 curve of a combinatorial signature of 20 miRNAs, whose differential expression is significant in 520 the first cohort, distinguishes between FTD and healthy controls of the second cohort. True 521 positive rate (sensitivity) as a function of the false positive rate (1-specificity) for different cut-522 523 off values. P-values are calculated given null hypothesis of area under the curve (AUC) =0.5. (D) ROC curves based on K-fold cross validation with N=3 for a merged data set of 136 miRNA 524 expression in both the discovery and the replication cohort (169 FTD cases and 56 healthy 525 controls). Red, ROC for fold 1; blue, ROC for fold 2; green, ROC for fold 3. 526

- 527
- 528
- 529
- 530



Figure 3. Most important miRNA classifiers in cross validation. Top 20 miRNA classifiers in (A) cross-validation fold 1 (B) fold 2 and (C) fold 3. (D-F) ROC curves based on K-fold cross validation with N=3 for a merged data set including both the discovery and the replication cohort (169 FTD cases and 56 healthy controls), when (D) only the 43 miRNAs depicted as "top 20" in at least one fold (all of the miRNAs shown in panels A-C) are selected for classification. (E) 13 miRNAs depicted as "top 20" in at least two folds are selected and (F) only the four miRNAs depicted as "top 20" in all three folds are selected. Red, ROC for fold 1; blue, ROC for fold 2; green, ROC for fold 3. 



**Figure 4. Differential miRNA expression in ALS vs. FTD plasma.** (A) Scatter plot of correlation between ALS/control ratio and FTD/control ratio. (B) Scatter plot of correlation between MS/control ratio and FTD/control ratio. (C) Venn diagram of comparison between ALS and FTD with 13 shared miRNAs in the black portion. (D) Venn diagram of comparison between MS and FTD with 5 shared miRNAs in the black portion.

#### 559 Supplementary figures



Figure S1. miRNA profiles of FTD subtypes. (A) MA plots of differential miRNA expression 561 in bvFTD patients (N=25), (B) SD patient (N=8) and (C) PNFA patients (N=15) compared to 562 healthy controls (N=21). Log-2 transformed fold-change, against mean miRNA abundance. Red 563 -significantly changed miRNAs (p-value  $\leq 0.05$ ). ROC curve of a combinatorial signature of 20 564 miRNAs, whose differential expression is significant in the first cohort, distinguishes (**D**) by FTD 565 566 (E) SD and (F) PNFA from healthy controls, in the first (black) and second (red) studies. True positive rate (sensitivity) as a function of the false positive rate (1-specificity) for different cut-567 568 off values. P-values are calculated given null hypothesis of area under the curve (AUC) =0.5. (G) MA plot for differential miRNA expression between PNFA (N=15) and non-PNFA FTD 569 cases (bvFTD + SD (N=33)). Red- significantly changed miRNAs (p<0.05). (H) ROC curve 570 based on combinatorial signature of 14 significant miRNAs for distinguishing PNFA and non-571 572 PNFA FTD cases.



Figure S2. miRNA profiles associated with FTD neuropathologies. (A) MA plots of differential miRNA expression in FTD patients with predicted Tau pathology (N=19) vs patients with predicted TDP-43 pathology (N=63) from both cohorts used in the study. Log-2 transformed fold-change, against mean miRNA abundance. Red -significantly changed miRNAs (p-value  $\leq 0.05$ ). (B) ROC curve based on combinatorial signature of 14 significant miRNAs for distinguishing FTD cases with Tau pathology from those with TDP-43 pathology.